IP Library Granted Patent US 10,611,755
Granted Patent B2
US 10,611,755 · App. 16/071,649 · Granted Apr 7, 2020

Aryl substituted pyrimidines for use in influenza virus infection

Inventors: Tim Hugo Maria Jonckers (Heist op den Berg, BE); David Craig McGowan (Brussels, BE); Jérôme Émile Georges Guillemont (Andé, FR); Werner Constant J Embrechts (Beerse, BE); Guillaume Jean Maurice Mercey (Montaure, FR); Christophe Francis Robert Nestor Buyck (Hamme, BE); Wendy Mia Albert Balemans (Kalmthout, BE); Pierre Jean-Marie Bernard Raboisson (Rosieres, FR)
Assignee: Janssen Sciences Ireland UC
C07D403/14A61K31/506A61K31/517A61K31/519A61K31/52A61K39/145A61K45/06A61P31/16C07D403/04C07D403/12C07D471/04C07D473/34C07D487/04C07D495/04C07D513/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,611,755
App. No.
16/071,649
Granted
Apr 7, 2020
Kind
B2
Abstract

The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.

Claims (11)

1. A compound having the structural formula

a stereo-isomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof.

2. A pharmaceutical composition comprising the compound according to claim 1 , stereo-isomeric form, pharmaceutically acceptable salt, solvate or polymorph thereof, and one or more pharmaceutically acceptable excipients, diluents or carriers.

3. A method of treating viral influenza infection in a patient, said method comprising administering to the patient in need thereof an effective amount of a compound having the structural formula

a stereo-isomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof.

4. The method of claim 3 , wherein the compound, stereio-isomeric form, pharmaceutically acceptable salt, solvate or polymorph thereof, is administered as a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients, diluents, or carriers.

5. The method of claim 3 , further comprising co-administering to said patient an additional therapeutic agent.

6. The method of claim 5 , wherein the additional therapeutic agent is selected from an antiviral agent or influenza vaccine, or both.

7. The method of claim 6 , wherein the additional therapeutic agent is an antiviral agent.

8. A method of inhibiting replication of influenza virus(es) in a biological sample, said method comprising administering to the biological sample a compound having the structural formula

a stereo-isomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof.

Assignments (11)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2021
From: JONCKERS, TIM HUGO MARIA; MC GOWAN, DAVID CRAIG; EMBRECHTS, WERNER CONSTANT JOHAN; BUYCK, CHRISTOPHE FRANCIS ROBERT NESTOR; BALEMANS, WENDY MIA ALBERT; RABOISSON, PIERRE JEAN-MARIE BERNARD
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 056604/0566 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2021
From: GUILLEMONT, JEROME EMILE GEORGES
To: JANSSEN-CILAG
Reel/Frame 056604/0820 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2021
From: GUILLEMONT, JEROME EMILE GEORGES; MERCEY, GUILLAUME JEAN MAURICE
To: JANSSEN-CILAG
Reel/Frame 056604/0924 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2021
From: JANSSEN PHARMACEUTICA NV
To: JANSSEN SCIENCES IRELAND UC
Reel/Frame 056605/0184 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2021
From: JANSSEN-CILAG
To: JANSSEN SCIENCES IRELAND UC
Reel/Frame 056605/0241 →
CHANGE OF NAME Recorded Jun 21, 2021
From: JANSSEN SCIENCES IRELAND UC
To: JANSSEN SCIENCES IRELAND UNLIMITED COMPANY
Reel/Frame 056637/0668 →
CHANGE OF NAME Recorded Apr 2, 2021
From: JANSSEN SCIENCES IRELAND UC
To: JANSSEN SCIENCES IRELAND UNLIMITED COMPANY
Reel/Frame 055815/0967 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2019
From: JONCKERS, TIM HUGO MARIA; MC GOWAN, DAVID CRAIG; EMBRECHTS, WERNER CONSTANT JOHAN; BUYCK, CHRISTOPHE FRANCIS ROBERT NESTOR; BALEMANS, WENDY MIA ALBERT; RABOISSON, PIERRE JEAN-MARIE BERNARD
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 047906/0226 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2019
From: GUILLEMONT, JEROME EMILE GEORGES; MERCEY, GUILLAUME JEAN MAURICE
To: JANSSEN-CILAG
Reel/Frame 047906/0403 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2019
From: JANSSEN PHARMACEUTICA NV
To: JANSSEN SCIENCES IRELAND UC
Reel/Frame 047906/0457 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2019
From: JANSSEN-CILAG
To: JANSSEN SCIENCES IRELAND UC
Reel/Frame 047906/0576 →
Priority Claims (1)
EP 16152095 · Jan 20, 2016 · regional
Continuity (1)
Related Publication 20190047989A1 · Feb 14, 2019